Anteris Technologies Global Corp. · NASDAQ:AVR
Anteris Technologies Global — Shareholder Meeting (May 2020)
34 slides from Anteris Technologies Global's shareholder meeting presentation, May 2020
Slide 1: Presentation by Wayne Paterson, Chief Executive Officer & Managing Director
Presentation by Wayne Paterson, Chief Executive Officer & Managing Director
Slide 2: Reproduction of this material in any form without the permission of Admedus is prohibited
Reproduction of this material in any form without the permission of Admedus is prohibited
Slide 3: Reproduction of this material in any form without the permission of Admedus is prohibited
Reproduction of this material in any form without the permission of Admedus is prohibited
Slide 4: Reproduction of this material in any form without the permission of Admedus is prohibited
Reproduction of this material in any form without the permission of Admedus is prohibited
Slide 5: Reproduction of this material in any form without the permission of Admedus is prohibited
Reproduction of this material in any form without the permission of Admedus is prohibited
Slide 6: Admedus Ltd AGM May 2020
A Admedus Ltd AGM May 2020
Slide 7: Developing the world’s most durable heart valve
Developing the world’s most durable heart valve Reproduction of this material in any form without the permission of Admedus is prohibited
Slide 8: COVID-19 preparedness and response
COVID-19 preparedness and response • Group continues to expect the coronavirus impact to be minimal • Alternate suppliers identified to source at-risk supplies and manufacturing inputs • Restricted manufacturing site access to required personnel only. Production team split and staggered to reduce un
Slide 9: 2019 – A year of transactions
2019 – A year of transactions Reproduction of this material in any form without the permission of Admedus is prohibited
Slide 10: 2019 – Restructuring for the future
2019 – Restructuring for the future Divestments enabled company to focus on high potential opportunity for DurAVR™ Infusion division • Low margin business sold for AUD $6.3 million • Company headcount reduced by 18 Immunotherapies • Admedus ceased funding in 2017 due to low probability of success an
Slide 11: Shifting to high potential opportunities with single focus
Shifting to high potential opportunities with single focus • 2019 saw multiple transactions and divestitures which enabled the company to exit lower margin lower potential businesses • Transactions raised non – dilutive capital for investment into significantly higher potential opportunities. • Tran
Slide 12: Financial highlights 2019/20
Financial highlights 2019/20 $17.1M $24.9M 75% Sales Revenue Profit on Sale Improvement in Result of divestments compared to prior year $16.1M 42.1 Cash Total Full Time (including term deposits) Equivalent Staff compared to decreased from 82.5 in the prior period $12.0M in prior year driven by two d
Slide 13: CY19 Financials
CY19 Financials $ millions CY2019 CY2018 Group revenue 17.1 25.6 • Group revenue of $17.1M Cost of sales (8.8) (13.2) – ADAPT® revenue: $10.2M – Infusion revenue: $6.9M Gross profit 8.3 12.4 • Gross profit margin 49% (2018: 49%) Other income 25.5 0.1 Selling, general and administrative costs (32.4)
Slide 14: Investments drive results
Investments drive results • Group continues to invest in Research & Development to accelerate its product development pipeline • Benefits of divestments flowing through Reproduction of this material in any form without the permission of Admedus is prohibited
Slide 15: Exchange rate driving AUD reported costs
Exchange rate driving AUD reported costs AUD 17.6M AUD 16.3M AUD 15.9M • USD $12.3M of expenses incurred in USD 12.3M 2019 converting into $A17.6M • The same USD $12.3M in 2017 converted into $A15.9M Reproduction of this material in any form without the permission of Admedus is prohibited
Slide 16: Developing the world’s most durable heart valve
Developing the world’s most durable heart valve Reproduction of this material in any form without the permission of Admedus is prohibited
Slide 17: Capitalizing on the multi-billion dollar TAVR opportunity
Capitalizing on the multi-billion dollar TAVR opportunity Market Potential of AVR as Treatment of SAS By 2025, Global Aortic TAVR CAGR 15.6% $10 Valve Replacement to Billions $8 $6 reach $8B USD* $4 $6.9B $2 $2.5B $- TAVR is expected to be 62% of 18 19 20 21 22 23 24 25 $1.1B $1.1B 20 20 20 20 20 20
Slide 18: Why a durable heart valve matters
Why a durable heart valve matters • The FDA approved the use of TAVR in “low risk” (younger) patients in 2019. • As a result replacement valves need to be durable and long lasting. Currently marketed TAVR valve showing significant calcification Reproduction of this material in any form without the p
Slide 19: Major studies of TAVR vs SAVR in low risk patients are underway
Major studies of TAVR “vs” SAVR in low risk* (younger patients) are underway *trials to be conducted over 10 years to assess differences between surgical replacement valves (SAVR) and transcatheter valves (TAVR) in low risk patients Reproduction of this material in any form without the permission of
Slide 20: Valves may need to last 15 years or more
FDA has approved TAVR in low risk (younger patients) 30 24 K Valves may need to last 15 years or more Women in younger patients treated with TAVR Men TAVR Volume (by age at implant) 25 20 K Structural Valve Deterioration (SVD) is Valve Durability the driving factor behind the need for Life Expectanc
Slide 21: Replacement valve deterioration is a key area of research
Replacement valve deterioration is a key area of research Reproduction of this material in any form without the permission of Admedus is prohibited
Slide 22: DurAVR addresses the key areas that lead to valve deterioration
DurAVR™ addresses the key areas that lead to valve deterioration … Only DurAVR™ is made from ADAPT® treated tissue with superior anti calcification properties Ca+2 DurAVR™ is made from one piece of tissue resulting in 35% less stress on the leaflets Other valves are constructed from Other valves are
Slide 23: DurAVR Durability experiments continue to be positive
DurAVR™ Durability experiments continue to be positive ACCELERATED WEAR TESTING SHEEP CALCIFICATION MODEL Admedus Valve shows no wear at 400 million cycles A hostile environment for valves Well Anchored Supple Clean Margins Day 1 200 million 400 million Sutures Cusps (Annulus) Competitor Valves demo
Slide 24: DurAVR is addressing the key issues impacting valve durability
DurAVR™ is addressing the key issues impacting valve durability 1. We have a unique tissue science (ADAPT®) which has zero DNA and proven not to calcify over 10 years in humans 2. 3D single-piece Aortic Valve (DurAVR™) which has shown no signs of wear over 450 million cycles (approx. 10 years ) 3. D
Slide 25: 2020 - Executing on the vision
2020 - Executing on the vision Reproduction of this material in any form without the permission of Admedus is prohibited
Slide 26: Key Clinical and Preclinical Programs
Key Clinical and Preclinical Programs 2020 Milestones First in Human DurAVR™ THV Conduit DurAVR™ SAVR Anti-Calcification Preclinical Proof of Concept Feasibility Clinical Comparison Study Animal Studies Animal Study Study Ca +2 • Confirm safety and clinical • Successful transcatheter access, • Confi
Slide 27: ADAPT Portfolio Patent Filings
ADAPT Portfolio Patent Filings ® YTD in 2020, the Company has filed 18 applications worldwide for its 3D valve and its novel sterilized packaging system. If all proposed additional filings due later in 2020 are filed, total patent applications filed on the ADAPT® portfolio will be 2X their 2019 leve
Slide 28: Key Opinion Leader Advocacy supports the science
Key Opinion Leader Advocacy supports the science ADAPT® PRESENTED AT MAJOR CONGRESSES • Dr. Paul Sorajja (Abbott Northwestern, Minneapolis) • World renowned interventional cardiologist • First podium presentation of our TAVR at 2019 Cardiovascular Innovations Conference (07/19) • Dr. Alan Zajarias (
Slide 29: DurAVR First in Human study patient #1
DurAVR First in Human study patient #1 TM Patients with other DurAVR surgical valves* Patient 1 (N>1400) Peak Gradient 23 11 Mean Gradient 11 5 EOA 1.9 2.9 * Average of 1400 patients implanted with commercially available surgical valves at Leuven University Hospitals Reproduction of this material in
Slide 30: Anteris – A new name for a new direction
Anteris™ – A new name for a new direction A new name to reflect the Company’s new positioning Anteris is associated with wasps • Wasps are: o Industrious o Team focused o Great engineers o Undaunted by larger foes o Aggressive Reproduction of this material in any form without the permission of Admed
Slide 31: Developing the world’s most durable heart valve
Developing the world’s most durable heart valve The right science • ADAPT® anti-calcification treatment is proven over 10 years in humans, with zero calcification in published studies The right design • The DurAVR™ 3D single-piece valve is proven to have less wear at the leaflets than conventional v
Slide 32: Capitalizing on the assets
Capitalizing on the assets Discussions are ongoing with several of the large MedTech companies Potential partnership deals could include: • Licensing of ADAPT® technology to existing in-market TAVR and SAVR products • Supply of ADAPT® treated material for current in-market products • Co development
Slide 33: World class TAVR specific advisory board
World class TAVR specific advisory board Gorav Ailawadi, MD Vinayak Bapat, MD Samir Kapadia, MD University of Virginia Health System New York-Presbyterian/Columbia Medical Cleveland Clinic Charlottesville, VA Center, New York, NY Cleveland, OH Susheel Kodali, MD Christopher Meduri, MD Michael Reardo
Slide 34: Opportunity Summary
OPPORTUNITY SUMMARY Total Aortic valve replacement market expected to be $7B USD or more by 2025 THE RIGHT TIME FDA has approved TAVR in younger, lower risk patients creates need for ultra-durable valve THE RIGHT TECHNOLOGY DurAVR™ 3D single-piece aortic valve with ADAPT® tissue technology ▶ Superio
Anteris Technologies Global — Shareholder Meeting (May 2020) on 6ix